Katherine N. Weilbaecher

Washington University in St. Louis — United States

Medicine · Health Sciences

54h-index9.0kcitations449works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and treatments(101), Cell Adhesion Molecules Research(80), Advanced Breast Cancer Therapies(63), HER2/EGFR in Cancer Research(49), Cancer Cells and Metastasis(46)

Publications449 total

Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways
Communications Biology·2026Open Access
Supplementary Figures S1-S10 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
2025Open Access
Supplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
2025Open Access
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025Open Access
Abstract P3-12-21: NeoTAILOR: A phase II biomarker-directed approach to guide neoadjuvant therapy for patients with clinical stage II/III ER+, HER2- negative breast cancer
Clinical Cancer Research·2025
Abstract P3-02-12: Hereditary breast cancer risk assessment and referral at a high-volume, diverse mammography clinic
Clinical Cancer Research·2025
Supplementary Data 1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
2025Open Access
Supplemental Table S1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
2025Open Access
Data from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
2025· 1 citedOpen Access
Abstract 1212: Disruption of Gαs/cAMP-mediated acid sensing by breast tumor cells blunts tumor-induced immune suppression and decreases bone metastases by enhancing cytotoxic T cell function
Cancer Research·2025· 2 cited
Abstract 5333: CDK4/6 inhibitors in patients with bone-only metastatic breast cancer, the role of immune microenvironment
Cancer Research·2025
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Clinical Cancer Research·2025· 5 citedOpen Access
Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid
BMJ Case Reports·2024· 1 cited
HTLV‐1 infected T cells cause bone loss via small extracellular vesicles
Journal of Extracellular Vesicles·2024· 3 citedOpen Access
Supplementary Figures S1-S10 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
2024Open Access
page 1 of 23Next →

Frequent Co-authors

David E. Fisher(10), Xinming Su(10), Angela C. Hirbe(8), Roberta Faccio(6), Deborah V. Novack(6), Michelle A. Hurchla(6), Hongju Deng(6), David Piwnica‐Worms(6), Julie L. Prior(6), Jochen G. Schneider(5), Jingyu Xiang(5), Özge Uluçkan(5), Elizabeth A. Morgan(5), Rebecca Aft(4), X. Cynthia(4), Melissa A. Meyer(4), David G. DeNardo(4), Sheila A. Stewart(4), Wei Zou(4), Foluso O. Ademuyiwa(4)